Company: COPL-UN
Filing Date: 2025-02-03
Form Type: S-1/A
Source: 0001829126-25-000620
Chunk: 13

Company: Copley Acquisition Corp
Filing Date: 2025-02-03
Form: S-1/A
Chunk 13
---
) the number of public shares then issued and outstanding. The proceeds deposited in the trust account could become subject to the claims of our creditors, if any, which could have priority over the claims of our public shareholders. Public shareholders will not have voting or redemption rights with respect to the first extension option and second extension option.

Because our sponsor acquired
the founder shares at a nominal price, our public shareholders will incur an immediate and substantial dilution upon the closing of this
offering, assuming no value is ascribed to the warrants included in the units. Further, the Class A ordinary shares issuable in connection
with the conversion of the founder shares may result in material dilution to our public shareholders due to the anti-dilution rights
of our founder shares that may result in an issuance of Class A ordinary shares on a greater than one-for-one basis upon conversion.
See the section titled “Risk Factors — Risks Relating to our Sponsor and Management Team — The nominal purchase price paid by our sponsor for the founder shares may result in significant dilution to the implied value of your public shares upon the consummation of our initial business combination, and our sponsor is likely to make a substantial profit on its investment in us in the event we consummate an initial business combination, even if the business combination causes the trading price of our ordinary shares to materially decline” on page 67. In addition, the cashless exercise of the placement warrants included in the placement units
purchased by our sponsor at the closing of this offering would increase the dilution to our public shareholders. Further, the conversion
of any working capital loans or extension loans into placement units, as well as the cashless exercise of the placement warrants that
are issued as part of such units, would further increase the dilution to our public shareholders.

The following table illustrates the difference between the public offering price per unit and our net tangible book value per share (NTBV), as adjusted to give effect to this offering and assuming the redemption of our public shares at varying levels and the exercise in full and no exercise of the over-allotment option. See section entitled “Dilution” on page 103 for more information.

| As of December 3, 2024 |                                                 |     |                |      |     |                |      |     |                |      |     |                |      |     |                |      |     |                |      |     |            |       |   |     |                |       |
|:-----------------------|------------------------------------------------: